SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001737287-21-000042
Filing Date
2021-10-07
Accepted
2021-10-07 16:20:41
Documents
12
Period of Report
2021-10-07
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K allo-20211007.htm   iXBRL 8-K 33014
  Complete submission text file 0001737287-21-000042.txt   169086

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20211007.xsd EX-101.SCH 1902
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20211007_lab.xml EX-101.LAB 24270
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20211007_pre.xml EX-101.PRE 12638
5 EXTRACTED XBRL INSTANCE DOCUMENT allo-20211007_htm.xml XML 10868
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 211312587
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences